Accendra Health Inc has 8 Schedule 13D or 13G filings on record since 2025-10-02. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Coliseum Capital Management, LLC | 16.9% | 13,100,807 | SCHEDULE 13D, 2025-11-14 | 2025-11-12 |
| BlackRock, Inc. | 7.1% | 5,454,051 | SCHEDULE 13G/A, 2025-10-02 | 2025-09-30 |
| Kevin M. Webb | 5.61% | 4,287,431 | SCHEDULE 13G, 2026-03-30 | 2026-03-12 |
| Charles Schwab Investment Management Inc | 4.75% | 0 | SCHEDULE 13G/A, 2026-05-14 | 2026-03-31 |
| Dimensional Fund Advisors LP | 4.5% | 3,507,559 | SCHEDULE 13G/A, 2025-10-09 | 2025-09-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Purpose of Transaction (Item 4)
Coliseum Capital Management, LLC
The Reporting Persons acquired the Common Stock for investment purposes, and such purposes were made in the Reporting Persons' ordinary course of business. In pursuing such investment purposes, the Reporting Persons may further purchase, hold, vote, trade, dispose or otherwise deal in the Common Stock at times, and in such manner (including pursuant to hedging transactions), as they deem advisable to benefit from changes in market prices of the Common Stock, changes in the Issuer's operations, business strategy or prospects, or from a sale or merger of the Issuer and evaluate plans and proposals for potential extraordinary transactions involving the Issuer such as potential business combinations, asset sales and financing transactions. To evaluate such alternatives, the Reporting Persons routinely will monitor the Issuer's operations, prospects, business development, management, competitive and strategic matters, capital structure, and prevailing market conditions, as well as alternative investment opportunities, liquidity requirements of the Reporting Persons and other investment considerations. Consistent with their investment research methods and evaluation criteria, the Reporting Persons may discuss such matters with management or directors of the Issuer, other shareholders, industry analysts, existing or potential strategic partners or competitors, legal, investment and financing professionals, sources of credit and other investors. Such factors and discussions may …The first part of Item 4 of the SCHEDULE 13D filed 2025-11-14; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-02 | BlackRock, Inc. | 7.1% | SCHEDULE 13G/A |
| 2025-10-09 | Dimensional Fund Advisors LP | 4.5% | SCHEDULE 13G/A |
| 2025-10-30 | The Vanguard Group | 7.71% | SCHEDULE 13G/A |
| 2025-11-14 | Coliseum Capital Management, LLC | 16.9% | SCHEDULE 13D |
| 2026-02-12 | Charles Schwab Investment Management Inc | 5.24% | SCHEDULE 13G |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-03-30 | Kevin M. Webb | 5.61% | SCHEDULE 13G |
| 2026-05-14 | Charles Schwab Investment Management Inc | 4.75% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Accendra Health Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.